middl
east
respiratori
syndrom
coronaviru
merscov
novel
zoonot
viru
caus
sever
respiratori
diseas
human
case
fatal
rate
close
vaccin
avail
evalu
util
promis
replicationdefici
simian
adenoviru
vaccin
vector
platform
establish
safeti
profil
human
dromedari
camel
merscov
vaccin
develop
use
transgen
lethal
balbc
merscov
mous
model
show
singl
dose
intranas
intramuscular
immunis
mer
encod
fulllength
merscov
spike
glycoprotein
highli
immunogen
confer
protect
lethal
viral
challeng
immunogen
efficaci
compar
immunis
rout
togeth
data
provid
support
evalu
mer
vaccin
human
dromedari
camel
anim
reservoir
infect
middl
east
respiratori
syndrom
coronaviru
merscov
first
emerg
saudi
arabia
march
laboratoryconfirm
case
relat
death
offici
report
world
health
organ
infect
geograph
link
saudi
arabia
travelrel
case
occur
europ
asia
africa
dromedari
camel
suscept
merscov
infect
appear
main
reservoir
viru
howev
humantohuman
transmiss
underli
rapid
spread
merscov
within
hospit
set
high
seropreval
antibodi
merscov
report
dromedari
camel
middl
east
variou
countri
africa
indic
widespread
merscov
circul
licens
vaccin
treatment
current
avail
merscov
infect
ongo
diseas
control
strategi
far
reli
minimis
contact
dromedari
camel
observ
standard
infect
control
measur
limit
nosocomi
transmiss
contact
trace
quarantin
address
unmet
need
merscov
intervent
prioritis
urgent
action
could
rapidli
achiev
one
health
approach
product
codevelop
use
human
prevent
diseas
camel
limit
viru
shed
block
subsequ
transmiss
human
leverag
vaccin
technolog
platform
establish
safeti
profil
target
speci
would
allow
rel
rapid
progress
product
develop
pipelin
mani
vaccin
platform
safe
evalu
human
vaccin
research
develop
camelid
infect
neglect
among
promis
human
vaccin
platform
replicationdefici
simian
adenoviru
vector
chad
boast
good
safeti
immunogen
profil
human
demonstr
clinic
trial
wide
rang
indic
includ
malaria
hiv
tuberculosi
influenza
hepat
c
ebola
other
one
chad
vector
term
undergon
test
dromedari
camel
show
excel
safeti
immunogen
encod
rift
valley
fever
viral
glycoprotein
recent
made
vaccin
construct
mer
encod
fulllength
merscov
spike
glycoprotein
genbank
access
number
target
protect
neutralis
antibodi
spike
glycoprotein
transgen
sequenc
insert
region
includ
human
tissu
plasminogen
activ
signal
sequenc
nterminu
express
control
human
major
immedi
earli
cytomegaloviru
promot
includ
intron
mer
shown
elicit
hightitr
merscov
neutralis
antibodi
robust
cell
respons
spike
glycoprotein
determin
mer
vaccin
efficaci
utilis
recent
develop
transgen
lethal
balbc
mous
model
van
doremalen
et
al
submit
express
human
dipeptidyl
peptidas
gene
locu
render
mice
suscept
merscov
infect
infect
merscov
mous
model
uniformli
lethal
dose
higher
merscov
infect
characteris
initi
respiratori
phase
secondari
encephalit
phase
similar
describ
previous
mer
vaccin
elicit
neutralis
antibodi
statist
signific
differ
detect
immunis
rout
mann
whitney
u
test
p
fig
merscov
neutralis
antibodi
respons
observ
among
vaccin
encod
enhanc
green
fluoresc
protein
egfp
vaccine
evalu
vaccin
efficaci
anim
challeng
intranas
day
postvaccin
tcid
merscov
strain
total
volum
observ
daili
sign
diseas
euthanasia
indic
loss
initi
bodi
weight
day
postinocul
dpi
four
anim
group
euthan
lung
collect
analys
remain
six
anim
per
group
sacrif
dpi
reach
human
endpoint
e
nucleocapsid
elisa
respons
n
per
group
experiment
procedur
perform
previous
describ
red
egfp
intranas
vaccin
anim
grey
mer
intranas
vaccin
anim
blue
egfp
intramuscularli
vaccin
anim
purpl
mer
intramuscularli
vaccin
anim
criteria
group
size
suffici
allow
detect
efficaci
mer
group
compar
control
power
use
twosampl
comparison
proport
alpha
determin
stata
statist
softwar
egfp
vaccine
develop
sign
diseas
includ
loss
bodi
weight
ruffl
fur
lethargi
fig
weight
loss
begun
dpi
dpi
mice
egfp
group
either
succumb
infect
reach
predefin
euthanasia
criteria
fig
sign
diseas
signific
loss
bodi
weight
observ
mice
vaccin
mer
fig
c
presenc
merscov
rna
lung
brain
analys
qrtpcr
mice
n
sacrif
dpi
high
viral
load
found
lower
respiratori
tract
brain
egfpvaccin
mice
intranas
tcid
eqg
tissu
confid
interv
ci
intramuscular
tcid
eqg
tissu
ci
viral
rna
detect
mer
vaccin
mice
fig
immunohistochemistri
stain
merscov
lung
tissu
show
abund
antigen
egfpvaccin
mice
vaccin
fig
merscov
replic
observ
type
type
ii
pneumocyt
fig
insert
respiratori
cell
endotheli
cell
bronchiolar
epithelium
macrophag
egfp
control
anim
merscov
antigen
observ
dpi
brain
mice
howev
emphasi
assess
vaccin
efficaci
respiratori
phase
diseas
brain
sampl
later
peak
viru
replic
respiratori
tract
dpi
collect
address
whether
singl
dose
mer
vaccin
truli
result
steril
immun
analys
pre
post
challeng
sera
merscov
nucleoprotein
elisa
irrespect
rout
immunis
rel
low
level
igg
antibodi
nucleoprotein
detect
fig
indic
anim
like
briefli
infect
first
day
inocul
result
morbid
mortal
signific
differ
merscov
nucleoprotein
respons
detect
vaccin
group
mann
whitney
u
test
p
fig
togeth
data
provid
support
evalu
mer
vaccin
human
dromedari
camel
rel
straightforward
given
establish
safeti
profil
platform
human
dromedari
camel
deploy
human
merscov
vaccin
need
safe
efficaci
atrisk
popul
includ
healthcar
worker
camel
herder
comorbid
highlight
ongo
whole
consult
ideal
target
product
profil
merscov
vaccin
howev
major
gap
remain
understand
key
immun
mechan
respons
protect
diseas
whilst
merscov
infect
elicit
high
titr
neutralis
antibodi
camel
appear
suffici
provid
longterm
protect
reinfect
identif
immun
correl
protect
merscov
human
camel
allow
costeffect
diseas
surveil
vaccin
monitor
summari
demonstr
util
platform
merscov
vaccin
develop
lethal
mous
immunohistochemistri
stain
merscov
antigen
lower
respiratori
tract
vaccin
mice
mous
tissu
evalu
patholog
presenc
viral
antigen
describ
previous
briefli
tissu
fix
neutralbuff
formalin
day
paraffinembed
tissu
section
stain
hematoxylin
eosin
h
e
inhous
produc
rabbit
polyclon
antiserum
use
primari
antibodi
detect
viral
antigen
grade
histopatholog
immunohistochemistri
done
blind
boardcertifi
veterinari
pathologist
lung
tissu
shown
insert
magnif
egfp
intranas
intramuscularli
c
vaccin
anim
show
multifoc
scatter
posit
lung
insert
display
merscov
antigen
within
type
ii
pneumocyt
mer
intranas
b
intramuscularli
vaccin
anim
show
merscov
antigen
posit
model
excel
immunogen
efficaci
observ
underpin
futur
evalu
mer
dromedari
camel
human
mice
randomli
assign
intranas
intramuscular
vaccin
infecti
unit
either
control
egfp
mer
vaccin
experi
perform
blind
experiment
knowledg
group
alloc
individu
mice
analys
sampl
sera
obtain
vaccin
day
post
vaccin
post
challeng
analys
viru
neutralis
assay
merscov
elisa
describ
previous
approv
anim
experi
obtain
institut
anim
care
use
committe
rocki
mountain
laboratori
perform
experi
done
follow
guidelin
associ
assess
accredit
laboratori
anim
care
intern
aaalac
certifi
staff
aaalacapprov
facil
follow
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
guid
care
use
laboratori
anim
work
infecti
merscov
strain
condit
approv
institut
biosafeti
committe
ibc
inactiv
remov
sampl
high
contain
perform
accord
ibcapprov
standard
data
gener
analys
studi
includ
publish
articl
